# Intra-Cellular Therapies, Inc.  Share Price Target ‘$80.72’, now 17.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc.share-price-target-80.72-now-17.7-upside-potential/4121142028
- Published: 2024-02-09T14:44:42+00:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** which can be found using ticker (ITCI) have now
16 confirmed analysts covering the stock with the consensus suggesting a rating 
of ‘buy’. The target price High/Low ranges between $101.00 and $59.00 with the average
share target price sitting at $80.72. (at the time of writing). Given that the stocks
previous close was at $68.57 this is indicating there is a potential upside of 17.7%.
The day 50 moving average is $66.66 and the 200 day moving average is $60.51. The
market capitalization for the company is 6.89B. The stock price for the company 
is currently $71.60 USD

 The potential market cap would be $8,111,609,602 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $4.40 and
a -14.4% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: